FERRITIN has long been recogniized as an intracellular Fe storage compound, but its occasional appearance in the circulation has been noted in some malignant states. Reissman and Dietrich (1956) , using a relatively crude method, detected ferritin in serum from 6 patients with Hodgkin's disease involving the liver, an observation later confirmed by Aungst (1968) who found ferritin in the serum of 30 patients with Hodgkin's disease. Bieber and Bieber (1973) used a semiquantitative technique to detect ferritin and found it in the serum of 44 /0 of 108 patients with Hodgkin's disease with a particularly high incidence in latestage nodular sclerosing disease.
A number of workers have shown that ferritin from a variety of tumours displays characteristics similar to that of foetal liver or placenta on isoelectric focusing and have suggested that the production of " carcinofoetal " ferritin may be a characteristic of malignant tissue (Jacobs and Worwood, 1975 (Carbone et al., 1971) . Histology of lymph node biopsies wsas classified according to the classification of Lukes and Butler (1966) as modified at Rye and Ann Arbour (Rappaport et al., 1971) . Serum ferritin concentration wNas estimated by the method of Jones and Worwood (1975) (Siegel, 1956 In the present group of patients, serum ferritin concentration showed a progressive and significant increase from Stage I to Stage IV disease (Table II) . In addition, the mean serum ferritin concentration in patients without systemic symptoms was less than half that in symptomatic patients (Table II) . However, a depression of serum Fe concentra- Fig. 1 shows the relationship between serum ferritin and transferrin saturation in normal subjects and patients with transfusional Fe overload. In these an increase in RE storage Fe is associated with a rise in transferrin saturation. In comparison, the Hodgkin's disease patients show no increase in transferrin saturation with increasing ferritin concentration. All patients with simple Fe overload who have a serum ferritin above 100 ,ag/l have a transferrin saturation above 250%.
The majority of Hodgkin's patients with serum ferritin within this range have a transferrin saturation below 20%. These findings are consistent with the operation of the hypothetical "' RE block " of Fe release.
In Fig. 2 the distribution of serum ferritin concentrations in the present group of patients is compared with that of normal women and those with early breast cancer (Jacobs et al., 1976) and active rheumatoid arthritis (Bentley and Williams, 1974) . It is interesting to note that in both malignant groups many of the abnormally high levels are similar to those found in the non-malignant inflammatory condition. The higher levels found in some Hodgkin's patients are usually associated with more advanced disease and are comparable to those found by Prieto, Barry and Sherlock (1975) in patients with a variety of liver disorders.
The data of Bieber and Bieber (1973) suggested that ferritinaemia occurred more commonly in association with certain histological types of disease. It appeared to be more common in patients with nodular sclerosing disease than in those with a histological picture of mixed cellularity. Only 3 patients with other histological types of tumour were examined. The present data (Table III)   165   11 do not indicate a significant difference either in serum ferritin or transferrinbound Fe concentrations related to differences in the histology of the tumour tissue.
The increase in serum ferritin concentrations that we have fouLnd in patients with Hodgkin's disease appears to be related to the activity and spread of the tumour. However, it can be adequately explained by the non-specific changes known to occur in the RE cells of all cancer patients (Cartwright and Lee, 1971) and by the occurrence of liver damage with release of hepatocellular ferritin in some cases. The possibility of abnormal ferritin production by the tumour remains, but so far there is no evidence to support this. The only instance of increased ferritin synthesis by malignant cells so far demonstrated is in the case of acute myeloblastic leukaemia (White et al., 1974) and in this condition the serum levels which result are higher than in the present series of patients.
The empirical value of serum ferritin estimation in evaluating clinical status or prognosis in treated patients has not been assessed, though if it responds as part of a non-specific reaction to the disease it may behave very similarly to more conventional, poorly understood indices of disease activity such as the erythrocyte sedimentation rate, serum Fe concentration or plasma protein changes.
